Updated: More recent research on SHP 465, now from Takeda after its purchase of Shire: A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder
Original post, 5/17/15
A longer-lasting version of Adderall XR is potentially in the pipeline.
After years of repeated setbacks, Shire announced earlier this month: It has struck a deal with the U.S. Food and Drug Administration (FDA) to move forward with its new longer-lasting Adderall product, for now called SHP465 (triple-bead mixed amphetamine salts – MAS), being evaluated as a potential treatment for ADHD in adults.
The protracted wrangling ended when Shire agreed to conduct a short-term efficacy and safety study in pediatric patients with ADHD (ages 6-17). Though Shire intends to win approval for this drug treating adult patients, the FDA wants more pediatric data in case it is also used in that population. (Most ADHD-targeting medications are used throughout the lifespan, despite specific approval for pediatric or adult usage).
Adderall and Adderall XR have lost patent protection, and Shire has stated that the 16-hour version represents a viable product. Shire’s patents for Vyvanse (lisdexamfetamine dimesylate) expire in 2023.
Company Press Release
In a press release, Shire says it anticipates the clinical trial’s first patient visit to take place in August 2015, with study completion targeted by the last quarter of 2016. More from the company:
Shire then expects to submit to the FDA by second quarter 2017 a Class 2 resubmission for approval of SHP465 as a treatment for ADHD in adults, which typically entails a 6-month review. Pending FDA approval, Shire anticipates launching the medicine in the second half of 2017. This update follows Shire’s announcement on October 9, 2014, that it was engaging the FDA to determine the parameters of clinical data requirements in order to submit the Class 2 resubmission….
…SHP465 demonstrated a statistically significant difference versus placebo at 16 hours post dosing, with onset of action starting 4 hours post dosing, as measured by the Permanent Product Measure of Performance (PERMP). Common adverse reactions in SHP465 registration trials (incidence ≥5% and at a rate twice placebo) in adults were: insomnia, decreased appetite, dry mouth, decreased weight, heart rate increased, and dysmenorrhea. These adverse events are generally known to be associated with the use of amphetamine products.
In other words, SHP465 might be as problematic as the immediate-release Adderall is for some people, as I wrote about in The Tragic Truth Of Adderall, or “Madderall.” Or it might provide welcomed longer-coverage for people who respond well to Adderall. It all depends on an individual’s response.
As the behemoth “Big Pharma” in ADHD treatment, Shire’s overall ADHD franchise in the U.S. extends to 2029. “With a launch planned for the second half of 2017,” according to the press release, “Shire expects that SHP465, following FDA approval, will have three years of Hatch-Waxman exclusivity and at least three patents listed in the FDA Orange Book expiring as late as May 2029.”